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ABSTRACT 
Traditionally milk replacer formulations for preweaned calves use milk protein sources 
(now principally whey proteins) because of their high digestibility, desirable amino acid profile, 
and lack of anti-nutritional factors.  Over the course of the past five years the price of milk-based 
proteins has continued to increase. As a result research has focused on finding more cost effective 
alternative protein sources to incorporate into milk replacers that result in similar performance 
compared to milk-derived protein formulations.  Therefore, the objective of this experiment was 
to determine the effects of calf milk replacers containing 0, 5, or 10% bovine plasma protein, either 
without or with supplemental Ile and Thr, on growth and health of Holstein bull calves (n = 104) 
for 56 d. The milk replacers were formulated to contain 22% crude protein (CP), 20% fat, and 
2.0% Lys.  Treatments were as follows (M): control, all milk protein MR, with Met added to 
achieve a Met:Lys ratio of 0.31; (5P): 5% addition of PP (plasma protein; 18% CP), with Met 
added to equal the ratio in treatment M; (5PA): 5% PP addition  as in treatment 5P, but with Ile 
and Thr added to equal the amount in treatment M; (10P): 10% addition  of PP (36% CP), with 
Met added to equal the ratio in  treatment M; and (10PA): 10% PP addition as in treatment 10P, 
but with Ile and Thr added to equal amount in treatment M.  Calves were fed the treatments twice 
daily at 12.5% solids at a rate of 10% of arrival body weight (BW) for the first 2 d, 12% of arrival 
BW for the remainder of the first week, and 14% of BW, adjusted weekly, until week seven.  
During the eighth week calves were fed once a day at 7% of BW and then weaned.  Starter was 
not fed until the sixth week for ad libitum intake.  Intake, health scores, and fecal scores were 
measured daily.  Body weight and growth measures were taken weekly and blood serum samples 
were taken during week 4.  
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 There was no effect of treatment on crude protein or metabolizable energy (ME) intake during the 
first five weeks.  There tended (P = 0.08) to be an effect of treatment on dry matter (DM) intake 
and during week 6 to 8, calves fed 10P tended (P = 0.09) to have decreased MR and ME intake 
relative to the other treatments.  Starter and total intake was not different among treatments.  The 
interaction of treatment by time was significant (P = 0.03) for body weight of calves with calves 
fed treatment 10P having the lowest BW during weeks 6 and 8 compared with the other treatments 
and lower BW than treatments 5P and 10PA in week 7.  Additionally, average daily gain (ADG) 
was lowest for calves fed treatment 10P.  There was a significant difference among treatments for 
gain:feed (kg/kg) with calves fed treatment 10P having the lowest efficiency.  There was no 
difference in withers height, hip height, body length, and hip width among treatments.  Heart girth 
and heart girth ADG had treatment by time interactions with calves fed treatment 10P having the 
smallest heart girth compared to the other treatments in week 7.  In the first 21 d, scours occurrence 
was higher in the control than for the milk replacers containing the higher inclusion of plasma 
protein both without and with supplemental Ile and Thr, and scours occurrence was also higher for 
the lower inclusion of plasma protein compared with the higher inclusion of plasma protein when 
amino acids were included.  Throughout the 56-d trial, the chance of antibiotic treatment was 
greater in the control milk replacer then all treatments except the higher level of plasma inclusion 
without supplemental amino acids and greater for the higher inclusion of plasma protein without 
supplemental amino acids compared with the other milk replacers with plasma protein.  Calves on 
treatments with the higher inclusion of plasma protein had fewer days of scours compared to the 
control and all of the milk replacers with plasma protein except the higher plasma protein without 
supplemental amino acids had fewer days of treatment with antibiotics compared to the all milk 
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control.  With inclusion of plasma protein there was no difference in performance and improved 
health was observed as long as formulations were balanced for Ile and Thr.    
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CHAPTER I. LITERATURE REVIEW 
 
NUTRTIENT REQUIREMENTS OF THE PRERUMINANT CALF 
 Dairy calves require nutrients for maintenance and growth.  Maintenance requirements 
result from the basic need to keep the calf alive, but also include body temperature maintenance, 
immune responses, and stresses that arise from transportation and the environment.  Growth, 
specifically new tissue accumulation, in dairy calves before weaning results as a function of 
primarily protein deposition in the bone and muscle (Drackley, 2008).   
The requirement for protein is determined by the requirement for indispensable or essential 
amino acids (EAA).  However, research on amino acid requirements in the preruminant calf under 
five weeks old is limited with very few estimates published.  Williams and Smith (1975) 
characterized the concentrations and changes of plasma amino acids and plasma urea in calves less 
than nine weeks old, and also estimated the Met requirement. Williams and Hewitt (1979) 
determined the lysine requirement and estimated the requirements for other EAA using the ratio 
to lysine with calves six weeks old or older.  Tzeng and Davis (1980) demonstrated the essentiality 
of lysine and methionine in the preruminant diet, which had previously not been substantiated.  
Additionally, Tzeng and Davis (1980) estimated the requirement of Lys to be 1.82% of dry matter 
(DM) and Met to be 0.65% of DM in milk-based diets.  Estimates were also given by Gerrits et al. 
(1997), but they were for veal calves between 80 and 240 kg.  More recently, Hill et al. (2008) 
evaluated the optimal concentrations of Lys, Met, and Thr in milk replacers (MR) for calves less 
than five weeks of age with the calves also receiving starter.  Their estimates when calves were 
fed 26% crude protein (CP) whey-based MR were 2.34% Lys, 0.72% Met, 1.27% Met+Cys, and 
1.8% Thr for maximized growth and efficiency (Hill et al., 2008), which is higher than estimates 
from earlier work (Williams and Smith, 1975; Williams and Hewitt, 1979).  Amino acid balancing 
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for preruminants is critical in successfully formulating diets to meet the maintenance and optimize 
growth of the calf, however, this is not addressed at all in the current NRC (2001).   In theory the 
preruminant calf’s amino acid requirements should closely mirror that provided from cows’ milk 
(Drackley, 2008).  Table 1 compares the requirement of essential amino acids to the amount 
provided in cows’ whole milk with estimates from Williams (1994) and other published literature.   
PHYSIOLOGY OF THE PRERUMINANT CALF 
 When a calf is born the compartments of the stomach are undeveloped with the abomasum 
as the predominant compartment, making the calf functionally a nonruminant (Davis and 
Drackley, 1998).   There are three phases of development from a preruminant to a functioning 
ruminant.  During the first phase, prior to solid feed consumption, the calf is entirely dependent on 
the nutrients provided in milk or MR digested by enzymes in the calf’s abomasum and small 
intestine.  The active enzymes in the preruminant phase are highly efficient at digesting milk 
proteins, lactose, and dietary triacylglycerol but are limited in the ability to digest non-milk 
proteins (Drackley, 2008).  In the abomasum there are two proteolytic enzymes, chymosin and 
pepsin, that are secreted in inactive form and then activated by hydrochloric acid (Davis and 
Drackley, 1998).  Chymosin is responsible for clot formation for calves fed milk or skim-milk 
based MR and the activity is highest at birth and declines as the calf reaches weaning, unlike pepsin 
(Davis and Drackley, 1998).  The activity of chymosin decreases when calves are fed diets without 
casein compared to diets formulated with skim milk (Garnot et al., 1977).  After leaving the 
abomasum, protein digestion continues with trypsin and chymotrypsin in the small intestine.  
Digestibility of milk proteins is high, but all protein digestibility improves with age (Davis and 
Drackley, 1998) so other non-milk sources of protein would be more readily accepted and used by 
the calf.  The second phase of development for the preruminant calf starts when the calf begins 
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consuming solid feed after the first two to three weeks of life, which initiates fermentation and 
development of the reticulorumen.  The third phase is the ruminant phase where the animal 
consumes only solid feed.   
MILK REPLACER HISTORY AND FORMULATION  
Milk Replacer History 
There are three options for the liquid portion of the preruminant’s diet including saleable 
milk, a mixture of waste and transition milk, and finally MR.  Generally, saleable milk costs the 
most when feeding calves because it can be sold off the farm for more money.  Waste and transition 
milk can be used effectively and for less money than saleable milk, but there are underlying costs 
and often inconsistencies in composition.  The use of MR has become a consistent and cost 
effective option on many dairy farms (Drackley, 2008).  In the United States, over 85% of heifers 
are fed MR for at least a portion of the preweaning period (NAHMS, 2011). Since their initial 
development in the 1950’s, MR quality and nutritional value has continually evolved.  Initially, 
calves were fed “gruels” that did not support optimum performance or health unless supplemented 
with whole milk (Otterby and Linn, 1981).  Milk replacers improved when dried skim milk or 
dried whey ingredients were included in the formulation and also as emulsification techniques 
were implemented to allow fat to be included (Davis and Drackley, 1998).   
Milk Replacer Formulation and Cost 
Conventional MR feeding programs limit-feed calves at 8-10% birth body weight (BW).  
Conventional MR typically contain 20 to 22% CP and 20% fat to maximize lean tissue growth at 
that intake (Bartlett et al., 2006).  Traditionally MR have been formulated using milk protein 
sources (now principally whey proteins) because of their high digestibility, desirable amino acid 
profile, and lack of anti-nutritional factors for preweaned calves (Davis and Drackley, 1998). The 
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digestive enzymes in the preruminant are designed to digest milk based proteins in the first few 
weeks of life (Tanan, 2005) and their capability to digest more complex non-milk proteins and 
carbohydrates increases in the first month of life (Le Heurou-Luron et al., 1992).  
 In formulation of MR, protein ingredients are a major portion of the cost and with 
increasing demand from the human market, milk derived proteins have become more expensive to 
include in MR formulations.  According to records from the United States Department of 
Agriculture (USDA) commodity average history for the last five years (Figure 1) the price of whey 
products including whey protein concentrate and whey protein have increased by an average of 
$0.29/kg and $0.12/kg, respectively.  Consequently, the price of MR have also increased by 
approximately $0.10/kg.  Figure 1 shows that the average MR price ($/kg) has increased over the 
course of the last five years from 2010 through 2014. 
According to estimates from the United Nations Population Division/DESA in 2009, the 
human population will increase to over 9 billion people by 2050.  As a result, it can be expected 
that demand, and consequently price, of milk-derived proteins will continue to increase.  
Therefore, research has focused on finding alternative protein sources to incorporate into MR that 
will result in similar performance compared to milk derived protein formulations, at a lower cost.   
Alternative Protein Sources 
With the increased milk protein ingredient cost, milk replacers frequently include 
alternative protein sources in formulations.  Most MR formulations with alternative protein sources 
do not replace all of the milk proteins.  Instead they typically replace less than 50% of the milk 
proteins, although as much as 60 to 70% has been replaced (Tomkins and Jaster, 1991).  Non-milk 
proteins generally have lower digestibility than the typical milk-based proteins included in MR 
(Davis and Drackley, 1998).  With inclusion of alternative protein sources, EAA may become 
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limiting and prevent maximum growth of the calves fed these diets because the AA profiles do not 
match milk proteins completely (Davis and Drackley, 1998).  There are several different 
alternative protein sources that have been researched including wheat, soy, egg, hydrolyzed red 
blood cells, and spray dried plasma protein.   
Wheat proteins have been fed in several forms.  Wheat gluten was shown to have a lower 
protein solubility and digestibility and has antigenic effects that skim milk does not (Kilshaw and 
Slade, 1982; Branco-Pardal et al., 1995).  Wheat proteins become more soluble when treated with 
acid to hydrolyze the proteins (De Laporte and Demeersman, 1991).   This also results in improved 
digestibility and decreased antigenicity, making hydrolyzed wheat protein more favorable to 
include in MR because of the improved physical properties, including solubility (De Laporte and 
Demeersman, 1991).  Several studies have shown similar growth rates when wheat proteins were 
compared to milk proteins (0.70 vs. 0.72 kg/d for female calves and 0.83 vs 0.77 kg/d for male 
calves, respectively; Terui et al., 1996 and Tomkins et al., 1994 a,b).  Additionally, the amino acid 
composition of wheat proteins is favorable when compared to whey proteins, except that wheat 
proteins are lower in Lys (Davis and Drackley, 1998).  A study done by De Laporte and 
Demeersman (1991), supplemented Lys in MR with partial replacement of skim milk with whey 
protein and modified wheat proteins and showed favorable results compared to dried skim milk 
MR.   
Soy proteins have also been incorporated in MR and are very popular as an alternative 
protein; however, there are still some limitations to their use (Drackley, 2008).  According to Lallès 
(1993), soy proteins are less digestible than milk proteins, especially in the first three weeks of life 
because of the immature digestive tract (Tanan, 2005).  Additionally, due to the anti-nutritional 
factors, including trypsin inhibitor, present in soybeans, if not processed, soy proteins result in 
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inferior calf performance (Huisman, 1989).  Soy products include soy flour, soy protein 
concentrates, and soy protein isolates.  Steam-heating raw soybeans results in soybean meal and 
soybean flour, which do not contain less of the anti-nutritional factors compared with unprocessed 
soy products (Lallès, 2000).  However, when soybean flour is fed to preruminants there are often 
poorer growth results and digestive disruptions because of sensitivity of young calves to protein 
quality (Lallès, 1993).  Further processing of soy with a solvent extraction results in soy protein 
concentrate and soy protein isolate.  These products are more refined and improve performance 
slightly over soybean meal products; however, with more extensive processing the antigenic 
properties can be reduced but at a greater cost (Lallès, 2000).  The AA provided by soy protein 
concentrate are lower in Lys, but overall the profile is decently balanced relative to Lys with the 
exception of Met and Thr, which are moderately lower than dairy calf requirements (Tanan, 2005; 
Drackley, 2008).  Calves fed soy flour in MR have improved gains when supplemented with EAA, 
including Thr, Met, and Lys, compared with calves not supplemented (Jenkins and Emmons, 1983; 
Kanjanapruthipong, 1998).   
Spray-dried whole egg provides a considerable amount of protein and fat and has an 
excellent AA profile (Quigley, 2002; Yamamoto et al., 1997).  Calves fed MR containing spray-
dried whole egg as a partial replacement of milk crude protein (up to 44% of CP) had linear 
decreases in average daily gain (ADG) as inclusion increased and the MR did not support adequate 
growth (Quigley, 2002).  Touchette et al. (2003) reported that liquid egg could be an effective 
alternative protein source when fed up to 10% of the diet on a conventional calf program.  There 
are some limitations in spray-dried whole egg including protease inhibitors and avidin, which 
binds biotin if not processed adequately (Quigley, 2002).   
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Spray-dried plasma proteins (PP) are very soluble and in pig diets have similar digestibility 
compared with skim milk proteins (Hansen et al., 1993).  The PP are good sources of AA, with the 
exception of methionine and isoleucine (Almeida et al., 2013).  Inclusion of up to 7.5% of blood 
products in swine dies has been successful when they were supplemented with isoleucine and 
threonine (DeRouchey, 2002).  Spray-dried PP are processed to maintain the functional 
characteristics of proteins, including albumin and IgG (Quigley and Wolfe, 2003), that maintain 
biological activity with additional non-nutritive value (Campbell et al., 2010).  Historically, 
inclusion of PP has been limited by cost relative to whey proteins (Drackley, 2008), however, 
inclusion of PP in calf MR is promising based on previous studies in swine and dairy calves.   
The proteolytic ability of calves under 3 weeks of age is limited and subsequently their 
ability to digest non-milk protein sources is decreased (Toullec and Guilloteau, 1989).  This may 
explain why there were poorer results for some of the non-milk protein sources included in MR.  
Additionally, although AA profiles of alternative protein sources may be similar to milk protein 
sources, there are discrepancies that could result in reduced growth compared to MR containing 
all milk protein sources.  The amount and profile of the AA supplied depends on the AA profile 
of the protein source, the processing of the protein, and the ability of the calf to digest the protein 
(NRC, 2001).  It is important to understand these factors when formulating and feeding alternative 
proteins.   
PLASMA PROTEIN IN SWINE DIETS 
 Spray dried porcine PP has been incorporated into weanling piglet diets with great success 
and has been shown to improve feed intake and reduce post weaning diarrhea (van Dijk et al., 
2001).   
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Growth 
During the transition from a liquid diet (milk) from the sow with highly digestible proteins, 
to solid feed that contains less digestible plant proteins, it is critical to provide more digestible 
ingredients that will minimize performance reductions (Everts et al., 1999).  It was initially shown 
by Gatnau and Zimmerman (1990 a, b), that diets containing PP resulted in greater ADG and 
increased feed intakes compared with the more traditional diet containing corn and soybean meal 
and milk products.  Further studies have used spray-dried PP to reduce the amount of skim milk 
or whey provided in the first starter diet successfully (Hansen et al., 1993; Kats et al., 1994).  
Inclusion rates that have maximized post-weaning performance have ranged from 6% (Gatnau et 
al., 1991; Gatnau and Zimmerman, 1992), 8 and 10% (Kats et al., 1994), or up to 13.4% (Hansen 
et al., 1993).  In a review by van Dijk et al. (2001) of weanling pig diets the authors determined 
that the optimum inclusion of porcine PP is up to 6% (total diet), which increases ADG and average 
daily feed intake in the first two weeks after weaning, and also reduces feed conversion ratio.  
There are some important considerations when incorporating PP into diets.  It has been proposed 
that some of the variability in performance responses due to PP inclusion rates may have resulted 
from differences in nursery environments (Coffey and Cromwell, 1995).  Gatnau and Zimmerman 
(1991) observed no difference in performance when pigs were fed 10% PP in an all-in-all-out 
nursery; however, there was a difference when pigs were housed in a continuous flow nursery.  
Similar results were observed in a study by Coffey and Cromwell (1995) in which they observed 
that performance of pigs housed in a more “controlled” nursery was higher compared with a more 
conventional nursery that would be similar to the continuous flow nursery in the study conducted 
by Gatnau and Zimmerman (1991).  Additionally, research conducted in pigs has demonstrated 
that Ile content in blood cells is limiting for growth (Kerr et al., 2004).  Lower responses to PP 
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may also result from low intakes of other EAA including Thr so proper AA balancing should be 
considered for optimal performance (van Dijk, 2001). 
Health  
 Although there is considerable concern related to post weaning diarrhea in piglets very few 
of the previous studies discussed have evaluated the occurrence of diarrhea in piglets fed PP.  A 
proposed mechanism for the improvement with PP inclusion is improvement of the 
immunocompetence from the immunoglobulins in PP (Coffey and Cromwell, 1995).  Gatnau et 
al. (1989) observed that immunoglobulins in PP were absorbed across the intestinal lumen into the 
blood stream and the colostrum-deprived piglets had titers for porcine parvovirus and porcine 
rotavirus.  The likelihood of this occurring in older pigs (3-4 weeks) is limited, but there may be 
some local protection from bacteria and viruses affecting the intestinal wall.  While the comparison 
in colostrum deprived new-born piglets and older weanling piglets is limited it appears that the 
immunoglobulins in PP have an effect on piglet health (Gatnau et al., 1995; Owen et al., 1995)).  
Weaning is associated with an increase in inflammatory cytokines (Pié, 2004), which affect 
intestinal barrier function and permeability (McKay and Baird, 1999).   Dritz et al. (1996) proposed 
that the immunoglobulin fraction decreases the exposure of the immune system to antigens 
resulting in reduced cytokines, which helps improve feed intake.    
PLASMA PROTEIN IN DAIRY CALF MILK REPLACERS  
 While incorporating PP into weanling piglet diets is quite common, research and 
implementation on the incorporation of PP into calf MR as a replacement of milk proteins has 
trailed in comparison.  This may have been due in part to the expense of PP relative to milk 
proteins.  However, as shown previously in this review the price of milk proteins has continued to 
increase in the last five years and as the demand for whey protein products continues to grow it 
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will likely become economically more difficult to use milk protein products in MR formulations 
for dairy calves.  As a result, renewed interest has been focused on spray-dried PP to be used in 
calf MR.     
Growth 
Plasma proteins have been evaluated in calf MR and have shown similar (Quigley and 
Bernard, 1996; Quigley and Wolfe, 2003) or improved (Morrill et al., 1995; Quigley et al., 2002) 
performance compared to all-milk protein MR.  There are no issues of solubility, handling, 
mixability, or palatability when PP is incorporated into calf MR (Quigley et al., 2002).  Morrill et 
al. (1995) fed calves MR with 25% of the protein replaced as either porcine or bovine PP.  They 
reported a significant advantage in BW gains for calves fed either MR containing PP versus a MR 
containing all milk proteins.  Additionally, Quigley and Wolfe (2003) fed calves MR containing 
either bovine or porcine PP at 20% of dietary CP and compared performance to calves fed a whey 
protein based MR.  Average BW for calves was not affected by treatment in this study.  However, 
when spray-dried bovine PP and porcine PP were compared BW gain tended to be higher for 
bovine PP but there was no difference when the PP MR were compared to the control (Quigley 
and Wolfe, 2003).  Quigley and Bernard (1996) observed similar growth performance in calves 
fed MR with PP (25% of dietary CP) compared to calves fed MR with all milk proteins.  In a study 
by Quigley et al., (2002) calves were fed MR containing 20% of CP as bovine PP with no 
significant effect on performance.  Merriman (2011) investigated the response of higher inclusion 
(>33% of the dietary CP) of PP in calf MR, however, as inclusion exceeded 33%, growth rates and 
efficiency were decreased.   
With the exception of Met, AA balancing in calf MR containing PP had previously not 
been evaluated until Merriman (2011).  In that experiment the MR formulated with PP were 
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supplemented with Ile to more closely match the AA profile of an all milk protein MR. Although 
Merriman (2011) observed that supplementation of isoleucine did not completely overcome the 
decreased performance as PP inclusion increased over 33%., results indicated that Thr might have 
become limiting for growth in young calves as PP inclusion increased even with Ile addition..  This 
indicates that higher inclusion of PP may be feasible if EAA balance is considered.   
Health  
 
According to the NAHMS (2011), 25.3% of preweaned heifers in the United States are 
affected with diarrhea, which is a major problem on dairies.  There is considerable interest in the 
potential for spray-dried PP as an opportunity to improve the health of calves.  Quigley et al. (2002) 
investigated the use of PP in MR for young calves and observed that calves fed MR with PP in 
experiment 1 tended to have lower fecal scores, lower use of electrolytes, and lower use of 
antibiotics than the all-milk control.  In experiment 2, calves fed MR containing PP had reduced 
mortality (4.4 vs. 20%) and tended to have lower fecal scores and fewer days with scours (fecal 
score >2).  Similarly, Quigley and Wolfe (2003) observed that calves fed MR with PP had lower 
mortality (7.5 and 5% vs. 25% for PP diets vs. whey protein concentrate diet), significantly fewer 
days with scours and tended to have lower fecal scores than calves fed the all-milk control.  They 
did not, however, observe a reduction in the use of medications compared with the control (Quigley 
and Wolfe, 2003).   
The impact of various stressors (e.g., co-mingling, disease challenge, weaning, transport) 
on immune activation may be partially reduced if the intestinal barrier function can be maintained 
(Campbell and Tyler, 2008).  Immune activation can result in reduced animal performance 
(Johnson, 1997; Spurlock et al., 1997) and can economically affect production functions like 
growth and lean tissue deposition (Campbell and Tyler, 2008).  There have been several studies 
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that have evaluated the ability of PP to reduce the effects of enteric challenges on dairy calves.  
Quigley and Drew (2000) orally challenged 36 calves with Escherichia coli to test the ability of 
spray-dried animal plasma compared to antibiotics to combat the enteric infection.  All of the 
calves showed signs of infection, but calves fed the antibiotics or the spray-dried PP had reduced 
mortality and morbidity compared with the calves only fed MR.  Arthington et al. (2002) orally 
challenged 12 three-week-old bull calves with a virulent coronavirus isolate to test the therapeutic 
efficacy of supplemental bovine serum.  Calves had improved respiration rate, packed cell volume, 
and feed intake when supplemented with the bovine serum and the authors concluded that this 
improved the recovery rate of those calves.  Twenty-four calves were challenged on d 8 of life 
with cryptosporidium oocysts to test the effectiveness of bovine serum concentrate to enhance 
bowel repair and facilitate clearance of cryptosporidium (Hunt et al., 2002).  Calves treated with 
bovine serum concentrate had a 33% reduction in volume of diarrhea at the peak of illness, 30% 
decrease in total gut permeability, 15% increase in villous surface area of the ileum and crypt 
depth, enhanced specific activity of intestinal lactase, and an almost four-fold decrease in 
cryptosporidial oocyst shedding.  The authors concluded that bovine serum concentrate reduced 
peak diarrheal volume, improved intestinal permeability, and facilitated intestinal repair in calves 
challenged with cryptosporidium.  Nollet et al. (1996) fed calves MR containing three levels of 
spray-dried PP (pasteurized to eliminate IgG activity) and then orally challenged the calves with 
Escherichia coli. They observed that calves fed the highest inclusion of PP (25g/L) were protected 
from the enteric challenge whereas the intermediate dose (10 g/L) had moderate protection and all 
calves not supplemented died within 7 d of the challenge.  They concluded that the protection of 
the calves with the plasma powder was due to the non-immunoglobulin fractions that it contained 
(Nollet et al., 1996).  Experiments in vitro have found that cattle plasma inhibits the adhesion 
13 
 
effects of glycoproteins including adhesion of Escherichia coli cells expressing F5+ or F17+ 
fimbriae (Mouricout and Julien, 1986, 1987; Sanchez et al., 1993).   
SUMMARY AND THESIS OBJECTIVES 
While PP may be included as an alternative protein in calf MR, refinement of inclusion 
rates and AA balancing is needed.  The benefits of spray-dried PP may go beyond being only an 
alternative protein but also offer an opportunity to improve health of dairy calves.  Therefore, the 
objective of this experiment is to determine the effects of calf MR containing 0, 5, or 10% bovine 
PP, either without or with supplemental Ile and Thr, on calf growth and health.   
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Data from Williams, A. P. 1994. Amino acid requirements of the veal calf and beef steer.  In: 
D’Mello J. P. F., editor.  Amino acids in farm animal nutrition.  Wallingford, Oxon (UK): CAB 
International. p. 329-349. and Labussière, E., G. Bertrand, and J. Noblet.  2007.  Establishing the  
 slaughter calf’s protein and energy requirements and variation factors.  Translated from: INRA 
Prod. Anim.  20 (5): 355-368.   
(1) Recommendations formulated by Toullec (1988): average recommended values for growth 
stages and finishing. 
 
 
Table 1.1.  Essential amino acid requirements (g/d) for a 50-kg calf gaining 0.25 kg/d, and 
comparison with cows’ whole milk.  
  Recommendations (% of lysine)   
Essential 
amino acid 
(EAA) 
Required 
(g/d) (1) (2) (3) (4) 
Cows’ milk 
(g/100 g 
EAA) 
Cows’ milk 
(% of 
lysine) 
Methionine 2.1 - - 26.9 - 4.6 31.7 
Cysteine 1.6 - - 20.5 - 1.4 9.6 
Methionine + 
cysteine 3.7 51 33 47.4 41 6.0 41.4 
Lysine 7.8 100 100 100 100 14.5 100 
Threonine 4.9 58 52 62.8 50 8.2 56.6 
Valine 4.8 72 60 61.5 ≤61 11.7 80.7 
Isoleucine 3.4 67 42 43.6 62 10.4 71.7 
Leucine 8.4 103 94 107.7 87 17.3 119.3 
Tyrosine 3.0 - - 38.5 - 9.0 62.1 
Phenylalanine 4.4 - - 56.4 - 8.7 60.0 
Phenylalanine 
+Tyrosine 7.4 99 46 94.9 ≤88 17.7 122.1 
Histidine 3.0 44 21 38.5 25 4.8 33.1 
Arginine 8.5 - - 109.0 - 6.4 44.1 
Tryptophan 1.0 11 15 12.8 50 2.5 17.2 
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Table 1.1 (Cont.) 
(2) Recommendations formulated by Foldager et al. (1977) from work studying the plasma 
concentration of methionine in male Holstein calves (40-45 kg) receiving five levels of 
methionine. 
(3) Recommendations formulated by Williams and Hewitt (1979) from work studying the 
nitrogen deposit and the apparent digestibility of nitrogen in male Friesian calves (50-58 
kg) receiving six levels of lysine. 
(4) Recommendations formulated by Van Weerden and Huisman (1985) from work studying 
the nitrogen deposit in male Dutch Friesian calves (50-70 kg) receiving three different diets 
according to essential amino acid concentrations.   
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Figure 1.1.  Average monthly milk replacer prices ($/kg) from 2010 until 2014.  Data from the 
United States Department of Agriculture, Agricultural Marketing Service.  2014.  Dairy Market 
News.  Accessed Jan. 20, 2015.  http://www.ams.usda.gov/AMSv1.0/DairyCommodity  
AveragesMain.  
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CHAPTER TWO.  AMINO ACID SUPPLEMENTATION OF CALF MILK 
REPLACERS CONTAINING BOVINE PLASMA PROTEIN 
INTRODUCTION 
In the United States, over 85% of heifers are fed milk replacer (MR) for at least a portion 
of the preweaning period (NAHMS, 2011).  Conventional (limit-fed) MR typically contain 20 to 
22% protein and 20% fat (dry basis) and are traditionally formulated using milk protein sources 
(now principally whey proteins) because of their high digestibility and desirable amino acid profile 
for preweaned calves (Davis and Drackley, 1998).  In MR formulation, however, protein 
ingredients are a major portion of cost.  With increasing demand from the human market, milk-
derived proteins such as whey protein concentrate have become increasingly more expensive.  
Identification of non-milk protein sources that provide similar growth and health but at lower cost 
continues to be an important research objective.   
Spray-dried plasma proteins (PP) are good sources of a balanced amino acid profile, with 
the exception of methionine (Met) and isoleucine (Ile; Almeida et al., 2013).  In addition, PP are 
processed to maintain the functional characteristics of proteins such as albumin and IgG.  Plasma 
proteins have been evaluated in calf MR and have resulted in similar (Quigley and Bernard, 1996; 
Quigley and Wolfe, 2003) or improved (Morrill et al., 1995; Quigley et al., 2002) performance 
compared with all-milk protein MR.  In these studies, PP has replaced milk proteins by up to 25% 
of total crude protein (CP).  In a study by Merriman (2011), the inclusion of PP was evaluated over 
a wide range of whey protein replacement in calf MR and results indicated that replacing up to 
33% of the total dietary CP with PP did not reduce performance.   
Research in pigs has demonstrated that Ile in dietary blood cell protein is limiting for 
growth (Kerr et al., 2004).  Results from the study conducted by Merriman (2011) indicated that 
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Thr might become limiting for growth in young calves as PP inclusion increases even with Ile 
addition.  Evaluation of amino acid supplementation with inclusion of PP may aid in the 
understanding and formulation of more cost-effective calf MR that perform similarly to 
conventional MR. 
The objective of this experiment was to determine the effects of calf MR containing 0, 5, 
or 10% bovine PP (as a percentage of total ingredients), either without or with supplemental Ile 
and Thr, on calf growth and health.    
 
MATERIALS AND METHODS 
Calves, Arrival, and Processing 
All procedures were conducted under protocols approved by the University of Illinois 
Institutional Animal Care and Use Committee.  The study was conducted from October 2013 to 
February 2014.  A total of 105 male calves, less than 1 wk old, were selected at a local farm in 
east-central Illinois.  At the time of selection, blood samples were taken from the jugular vein into 
a 10-mL evacuated serum separation tube (Becton Dickenson, Rutherford, NJ).  Blood was 
centrifuged at 1300 × g for 15 min and a refractometer was used to determine total protein 
concentration in the serum for all potential calves.  Calves were selected based on total protein and 
visual health assessment.  All calves selected were given 2 mL BO-SE (Merck Animal Health, 
Kenilworth, NJ), 1 mL of Vitamin A and D (Sparhawk Laboratories, Inc., Lenexa, KS), and 2 mL 
of Inforce (Pfizer, New York, NY).  If a calf was chosen for the trial and had a total protein of <5.5 
g/dL the calf was given 50 mL of Bovisera (Colorado Serum Co., Denver, CO) and 20 mL of C 
and D antitoxin (Boehringer Ingelheim, Ridgefield, CT).  After selection, calves were transported 
to the University of Illinois Nutrition Field Laboratory research site.  In total three groups of calves 
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were selected from the dairy.  In each group, all treatments were equally represented within blocks 
and once all calves were enrolled there were 21 calves per treatment.   
Initial measurements of body weight (BW), body length, heart girth, withers height, hip 
height, and hip width were obtained after arrival at the research facility.   
 
Housing 
Calves were housed in south-facing individual hutches (Calf-tel, Hampel Corp., 
Germantown, WI) placed ~1.5 m apart.  Hutches were placed on a base of crushed rock, covered 
by landscape cloth and a layer of straw.  Straw was checked daily and more added as needed.  
Temperature and humidity were recorded using data from the local weather station. 
 
Experimental Diets 
Calves were blocked on the day of arrival (d 0) by BW and serum total protein 
concentration and then randomly assigned within block to one of the five MR treatments.  All 
treatments resembled a commercial formula containing 22% CP and 20% fat and were formulated 
to contain 2.0% Lys (Table 1).   
The treatments were as follows: M: control, all milk protein MR, with Met added to achieve 
a Met:Lys ratio of 0.31; 5P: 5% addition of PP (18% of CP), with Met added to equal the ratio in 
treatment M; 5PA: 5% PP addition  as in treatment 5P but with Ile and Thr added to equal the 
amount in treatment M; 10P: 10% addition  of PP (33% of CP), with Met added to equal the ratio 
in  treatment M; and 10PA: 10% PP addition as in treatment 10P but with Ile and Thr added to 
equal amount in treatment M.  Milk replacers were manufactured by Milk Specialties Global 
Animal Nutrition (Eden Prairie, MN).   
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Feeding and Management 
Calves were fed twice daily at 0500 h and 1630 h.  All MR were reconstituted to 12.5% 
solids.  For the first 2 d after arrival MR were fed at a rate of 10% of arrival BW.  For the remainder 
of the first week (d 3-7) calves were fed MR at a rate of 12% of arrival BW.   Beginning on d 8 
MR was fed at a rate of 14% of BW, adjusted weekly.  Milk replacer intake was recorded daily.  
During the eighth week (d 50-56) calves were given MR only one time per day and after d 56 MR 
was no longer fed.  Water was offered for ad libitum consumption and intake was recorded daily.  
Calf starter was fed beginning in the sixth week (d 36) for ad libitum intake and intake was 
measured daily.  No starter was offered during the first 5 wk so that potential differences in MR 
protein source and amino acid balance could be detected with greater sensitivity.   
 
Health 
Health checks were performed daily.  Fecal scores were assigned on a 1 to 4 scale: 1 = 
normal and well formed; 2 = soft but still holds form; 3 = loose without form; and 4 = consistency 
of water.  Respiratory scores were assigned on a 1 to 5 scale: 1 = normal; 2 = open mouth breathing; 
3 = open mouth breathing with mucus; 4 = dry cough, and 5 = wet cough.  Overall appearance and 
behavior also were recorded.  After arrival rectal temperature was measured daily for 5 d and at 
any time when a calf showed signs of illness throughout the duration of the study. Flunexin 
meglumine (Phoenix Pharmaceutical, Inc., St. Joseph, MO) was administered to calves with a 
rectal temperature of 40˚C or above.  Navels were dipped in povidone iodine as needed until dry.  
Animals were monitored multiple times daily for illness and dehydration status and treated as 
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needed.  Hydration status was assessed using fecal scores, skin tent test, eye appearance, and 
overall attitude.  An electrolyte solution (Land O’Lakes, Inc. Arden Hills, MN) was administered 
as needed.  Calves were administered vaccinations following standard procedures of the facility.  
Calves were not castrated until after completion of the study.   
 
Feed Analysis 
Milk replacers were sampled once weekly and stored at –20˚C until analysis.  Composite 
samples were prepared for each batch of calves and were analyzed by Dairy One (Ithaca, NY) for 
DM, CP, fat, ash, Ca, P, Mg, K, Na, Fe, Zn, Cu, Mn, Mo, and S by standard wet chemistry methods 
(www.dairyone.com.).  Values for ME were estimated from chemical composition as described 
(www.dairyone.com). Composite samples also were sent to the University of Missouri 
Agricultural Experiment Station Laboratory (Columbia, MO) for complete amino acid analysis by 
cation-exchange chromatography coupled with post-column ninhydrin derivatization and 
quantification.  The laboratory used base-catalyzed hydrolysis so that tryptophan content could be 
determined.   
Starter was sampled weekly when it was being fed and stored at -20˚C until analysis.  
Composite samples were prepared for each batch of calves and analyzed by Dairy One using wet 
chemistry techniques for DM, CP, lignin, fat, ash, starch, ME, Ca, P, Mg, K, Na, Fe, Zn, Cu, Mn, 
Mo, S, and Cl. 
 
Body Growth and Measurements 
Body weight, body length, heart girth, withers height, hip height, and hip width were 
measured upon arrival and weekly thereafter for the duration of the trial.  Body weight and growth 
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measures were obtained at 1200 h on the day specified for each group of calves based on their 
arrival date.     
 
Blood Collection and Analysis 
 Blood was sampled at the end of wk 4 before the morning feeding and 4 h after the morning 
feeding.  Blood was collected via jugular venipuncture into 10 mL evacuated serum separation 
tubes (Becton Dickenson, Rutherford, NJ).  Blood was allowed to clot and then centrifuged at 1300 
× g for 20 minutes.  Serum was divided into aliquots in polypropylene tubes and stored at -20˚ C 
until analyzed.   
 Serum samples were analyzed for concentrations of urea N (mg/dL), total protein (g/dL), 
and albumin (g/dL) at the University of Illinois College of Veterinary Medicine diagnostic 
laboratory (Urbana, IL) using automated enzymatic analysis procedures.  Total globulin (g/dL) 
was calculated as the difference between total protein and albumin.   
 
Economics 
The cost of the MR per kilogram and per kilogram of gain were calculated for each 
treatment.  The prices were quoted by Steve Younker at Milk Specialties Global on 17 July 2014 
and are for comparison only.   
 
Statistical Analysis 
 Data were checked for homogeneity of variance and normality assumptions throughout by 
residual plots and Shapiro-Wilk test using PROC UNIVARIATE in SAS v 9.4 (SAS Inst. Inc., 
Cary, NC).  Analysis of variance was conducted for feed samples using the GLM procedure in 
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SAS.  The Tukey adjustment was used to determine differences among treatments. Analysis of 
variance was conducted using the MIXED procedure in SAS for growth and intake parameters.  
Calf and block were defined as random effects, while treatment was defined as a fixed effect.  For 
variables with repeated measurements, a covariate (initial measurement) was used to analyze the 
data.  Calf within block was the subject for repeated measurements, and several covariance 
structures were evaluated and the one that minimized the adjusted and unadjusted Akaike 
Information Criteria (AAIC and AIC), the Bayesian Information Criteria (BIC), and –2 Ratio Log-
likelihood with the least number of parameters was chosen.   
Frequency of electrolyte administration, scours occurrence, and respiratory illness were 
evaluated first using a simple Chi-square statistic.  Models for occurrence of scours and treatment 
with antibiotics then were evaluated by logistic regression using a binomial distribution in the 
GLIMMIX procedure in SAS.  Odds ratio (OR) was used to compare the likelihood of two 
treatments to incur any event.  Duration of scouring and administration of medication were 
evaluated with a Poisson distribution using the GENMOD procedure (SAS Inst. Inc.).  
Significance was declared at P < 0.05 and trends discussed when 0.05 < P < 0.10. Least squares 
means were calculated and are presented with standard errors. 
 
RESULTS 
 
Environment 
 Three replicates of calves were brought to the Nutrition Field Laboratory at different times 
throughout the course of the study.  For the first group of calves (numbers 1 to 40) the daily mean 
high temperature was 14˚C and the low temperature was 2˚C.  The second group of calves 
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(numbers 41 to 60) had a daily mean high of 7˚C and a low of –3˚C.  The third group of calves 
(numbers 61 to 105) had a daily mean high of –1˚C and a low of –11˚C.  The effect of replicate 
was included in the original models and interactions of treatment with replicate were evaluated, 
however, there were no significant interactions. 
 
Nutrient Composition of Diets 
 Analyzed chemical composition of MR is shown in Table 2.  The MR were formulated to 
contain 22% CP, which was achieved for all treatments.   
 Amino acid analyses of MR on a DM basis are shown in Table 3.  Analyzed Lys for the 
control (M) was 1.90% and ranged from 1.88% for treatment 5PA to 1.95% for treatment 5P and 
10P but there were no differences (P = 0.52) in amount provided among treatments.  With this 
formulation and the feeding rate Lys should have been limiting and calves should have been 
responsive to differences in protein digestibility or amino acid balance.  Additionally, there were 
no differences (P = 0.69) in analyzed Met between the treatments.  As designed there was a 
difference (P < 0.0001) in analyzed Ile among treatments.  Treatment M and 5PA provided the 
most Ile with 1.32 %, whereas treatments 5P and 10PA providing 1.20 and 1.17%, respectively, 
and treatment 10P only provided 1.06% Ile in the diet.  Although treatments 5PA and 10PAwere 
supplemented with Thr there was no difference (P = 0.16) in the amount provided among 
treatments.  The amino acid composition relative to Lys is shown in Table 4.  Methionine was 
formulated at 31% of Lys (i.e., 0.63% of dietary DM).  Analyzed Met content was 30.1% for the 
control and relative Met contents ranged from 23.3% to 28.3% for the other treatments, but there 
was no difference (P = 0.59) among treatments.  Analyzed Ile of the control diet was 69.4% of 
Lys.  Supplementation of Ile increased the concentration relative to the respective un-
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supplemented MR with PP for the 5% inclusion rate of PP.  Treatment 5PA supplied Ile at 69.9% 
of Lys, similar to the control diet as desired; however, treatment 10PA did not achieve the same 
Ile value as the control and provided similar amounts relative to Lys as treatments 5P and 10P.  
Analyzed Thr content of the control diet was 78.4% of Lys.  Supplementation of Thr numerically 
increased the concentration relative to Thr in the un-supplemented MR with PP, but this difference 
did not achieve significance (P = 0.07).   
 
Intakes 
 Overall intakes of DM, CP, metabolizable energy (ME), and Lys for MR for wk 1 to 5 and 
wk 6 to 8 are shown in Table 5.  During wk 6 to 8, there tended (P = 0.08) to be a difference of 
MR intake with calves fed treatments M, 5P, 5PA, and 10PA consuming 897, 912, 906, and 913 
g/d, respectively, while calves fed treatment 10P consumed 863 g/d.  During wk 6 to 8, there 
tended (P = 0.09) to be a difference of ME intake from MR with calves fed treatments M, 5P, 5PA, 
and 10PA consuming 4054, 4093, 4000, and 4058 kcal/d, respectively, while those fed treatment 
10P consumed 3863 kcal/d.  There was a significant treatment (P < 0.0001) difference for Lys 
intake (g/d) during wk 1 to 5 with calves fed treatments 5P and 10PA consuming 15.5 and 15.5 
g/d, while treatment M, 5PA, and 10P consuming 14.7, 14.8, and 14.6 g/d, respectively.  There 
was also significant treatment (P < 0.0001) difference for Lys intake during wk 6 to 8 (from MR 
only) with calves fed treatments 5P and 10PA consuming 18.3 and 18.4 g/d, while treatment M, 
5PA, and 10P consuming 17.2, 17.3, and 16.7 g/d, respectively. These differences in Lys intake 
reflect small differences in DMI and analyzed Lys concentrations in the MR.   
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 Overall intake for starter and total intake of MR plus starter for wk 6 to 8 are also shown 
in Table 5.  There were no differences in intakes of DM, CP, or ME for starter and, consequently, 
for combined intakes of MR and starter during wk 6 to 8.   
 Milk replacer intake for wk 1 to 8 is shown in Figure 1.  There was no difference in MR 
intake (g/d) over the 8 wk; however, calves fed treatment 10P had numerically lower intakes than 
the other treatments in wk 6 and 7.  This corresponded to the trend detected in analysis of data 
from wk 6 to 8 as described earlier.   
 
Growth 
 Mean BW, ADG, feed efficiency (gain:feed), and growth measurements for the first 5 wk 
are presented in Table 6.  Initial BW was not different among treatments (P = 0.97).  There was a 
significant (P = 0.03) treatment difference for gain:feed (kg/kg) with calves fed treatment 10P 
having the lowest efficiency (0.54 kg/kg), while treatment M, 5P, 5PA, and 10PA achieved 
efficiencies of 0.61, 0.65, 0.62, and 0.65 kg/kg, respectively.  Treatment by time interactions were 
significant for heart girth (P = 0.03) and heart girth ADG (P = 0.02) with calves fed treatment 10P 
having the lowest heart girth (84.8 cm) and lowest heart girth ADG (0.24 cm/d) compared to the 
other treatments.   
 
Mean BW, ADG, feed efficiency (gain:feed), and growth measurements for all weeks are 
presented in Table 7.  There was no difference in final BW at the end of wk 8 (P = 0.12).  The 
interaction of treatment by time was significant for BW of calves (P = 0.03).   Figure 2 shows the 
changes in BW over time.  During wk 6 and 8, treatment 10P had the lowest BW compared to all 
other treatments, and in wk 7 treatment 10P had lower BW than treatment 5P and 10PA.  The 
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effect of treatment was significant (P = 0.05) for ADG with calves fed treatment 10P having the 
lowest gains (670 g/d), while treatment M, 5P, 5PA, and 10PA achieved 723, 774, 720, and 752 
g/d, respectively.  There was a significant (P = 0.01) treatment difference for gain:feed (kg/kg) 
with calves fed treatment 10P having the lowest efficiency (0.58 kg/kg), while treatment M, 5P, 
5PA, and 10PA achieved efficiencies of 0.64, 0.68, 0.65, and 0.67 kg/kg, respectively.   
 Withers height, hip height, body length, and hip width were not different among treatments.  
Heart girth and heart girth ADG both had significant (P = 0.006 and P = 0.04, respectively) 
treatment by time interactions.  Figure 3 shows heart girth over the 8 wk that the experimental MR 
were fed.  In wk 7 calves fed treatment10P had the smallest heart girth compared to all other 
treatments.   
 
Blood Metabolites 
 Concentrations of total protein, urea N, albumin, and total globulin are presented in Table 
8.  There was no difference among treatments for total protein or urea N (P > 0.10).  There was a 
significant (P = 0.007) difference among treatments for serum albumin concentrations with 
treatment 5P having the highest (2.88 g/dL) while all other treatments averaged 2.72 g/dL.  There 
was a tendency (P = 0.07) for a treatment by time interaction for globulin.  Treatment 5P had the 
lowest concentration of globulin (2.26 g/dL) and treatment 10PA had the highest (2.46 g/dL), with 
the other treatments intermediate.   
 
Health 
 Figure 3 shows the survival analysis of the calves fed the MR treatments.  A total of 105 
calves (21 calves per treatment) were obtained.  One calf from treatment 5PA was not included in 
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the final analysis because it was sick at arrival and did not recover.  Overall, two calves from 
treatment M died.  One died of bloat on day 52 of the study and the second calf was euthanized 
because of an abscess on the spine on day 32.  One calf each from treatments 5PA, 10P, and 10PA 
died during the course of the experiment.  The calf on treatment 5PA died from bloat on day 12.  
The calf on treatment 10P was euthanized because of frost-bite on day 46. The calf on treatment 
10PA died from a clostridial infection on day 14.   
 Table 9 shows initial total protein concentration in blood, average fecal score, and 
electrolyte intake.  Initial total protein did not differ (P > 0.10) among treatments.  Average fecal 
score during the first 21 d did not differ among treatments.  Additionally, there was no difference 
in mean total amount of electrolytes administered per calf over the study. Although the repeated 
measures analysis of weekly electrolyte intake resulted in significant effects of treatment, time, 
and the treatment by time interaction (Table 9), the values were not normally distributed and thus 
this analysis must be viewed with caution. 
The frequency of electrolyte administration is shown in Table 10.  During wk 2 the Chi-
square analysis tended to be different (P = 0.08), with calves receiving treatment M having the 
greatest number of calves given electrolyte solution.  The frequency of scours (fecal score >2) was 
highest in the first 4 wk (Table 10).  Little respiratory illness was observed among any treatment 
groups during the study (Table 10). 
 Table 11 shows the logistic models for the occurrence of scours (score > 2) and medication 
with antibiotics.    In the first 21 d, scours occurrence was higher for calves fed treatment M than 
for those fed treatments 10P and 10PA (OR = 1.38, P = 0.04 and OR = 1.62, P = 0.004, 
respectively), and scours occurrence for treatment 5PA tended to be higher than for treatment 
10PA (OR = 1.18, P = 0.09).  The chance of antibiotic treatment was greater in treatment M than 
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in treatments 5P, 5PA, and 10PA (OR = 2.60, P = 0.0003; OR = 3.41, P < 0.0001; OR = 2.47, P = 
0.0004), greater for treatment 10P than treatment 10PA (OR = 2.04, P = 0.007), and lower in 
treatments 5P and 5PA than treatment 10P (OR = 0.46, P = 0.005; 0.35, P = 0.0007). 
 Table 12 shows the logistic models for the number of days with scours and the duration of 
treatment with antibiotics.  All treatments were compared to the control (M).  When compared to 
treatment M calves fed treatments 10P and 10PA had fewer days of scours (2.69 d, P = 0.06 and 
2.21 d, P = 0.005, respectively).  Calves in treatments 5P, 5PA, and 10PA had fewer days of 
treatment with antibiotics when compared to calves in treatment M (0.9 d, P = 0.003; 0.7 d, P < 
0.001; and 0.95 d, P = 0.0005, respectively).  Contrast statements also were used to compare 
treatment means (Table 12).  For days with scours, the contrast of the linear effect of increasing 
PP without supplemental amino acids (treatments M, 5P, and 10P) approached significance (P = 
0.06) and the linear effect of increasing PP with supplemental amino acids (treatments M, 5PA, 
and 10PA) was significant.  For days medicated, the contrast comparing plasma-supplemented 
diets without and with supplemental amino acids (treatments 5P and 10P vs. treatments 5PA and 
10PA) was significant, as was the linear effect of increasing PP with supplemental amino acids 
(treatments M, 5PA, and 10PA). 
 
Economics 
The cost of the MR per kilogram and per kilogram of BW gain are shown in Table 13.  The 
cost difference per kilogram relative to treatment M was $0.13, $0.12, $0.26, and $0.22 less for 
treatments 5P, 5PA, 10P, and 10PA, respectively.  The average cost per kilogram of ADG in the 
first 5 wk, when only MR was fed, is also shown in Table 13.  The calculated cost per kg of ADG 
was $6.18, $5.67, $5.89, $6.91, and $5.51 for treatments M, 5P, 5PA, 10P, and 10PA, respectively. 
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DISCUSSION 
The goal of the current trial was to evaluate the response to plasma inclusion rates of 5% 
or 10% (18 and 36% of dietary CP, respectively) of the formulation either without or with 
supplementation of both Ile and Thr.  Several previous studies have evaluated lower levels (<25% 
of dietary CP) of inclusion of PP into calf MR fed in more restricted amounts than the current 
study.  Morrill et al. (1995) reported an advantage in BW gains for calves fed a MR containing PP 
versus a MR containing all milk proteins.  Quigley and Bernard (1996) observed similar growth 
performance in calves fed MR with PP (25% of dietary CP) compared to calves fed MR with all 
milk proteins.  Merriman (2011) investigated the response of higher inclusion (>33% of the dietary 
CP) of PP in calf MR; as inclusion increased over 33% growth rates and efficiency were decreased.  
Merriman (2011) tested the effect of supplementing MR with Ile formulated with PP to match the 
amino acid profile of an all milk protein MR; she found that the effect of Ile supplementation did 
not overcome the decreased performance as PP inclusion increased over 33%.  The results of that 
study indicate that Thr might have become limiting at higher inclusion rates of PP.   
In the current study, ADG and gain:feed decreased for calves fed the higher inclusion of 
PP without supplementation of amino acids; however, that limitation was overcome when amino 
acids were supplemented at the higher inclusion.  Intakes of DM, CP, and ME were not different 
among treatments, but gain:feed was lower for calves fed the higher plasma inclusion without 
amino acids (10P). The lower ADG and efficiency were not reflected in most body stature 
measurements except heart girth during wk 7 when calves fed 10P had the lowest heart girth 
compared to the other treatments.  Our results indicate that bovine PP supported growth equivalent 
to whey proteins when the amino acid profile was maintained similar to that of whey proteins.   
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The serum concentration of albumin was within the normal range but globulin levels for 
all treatments were below the normal range according to the Merck Veterinary Manual (2012).  
The observed values for calves fed treatment 5P indicated that serum albumin concentration was 
higher and total globulin concentration was lower for that treatment.  Albumin is influential in the 
oncotic pressure and low values allow fluid to move from the vascular space.  With low albumin 
concentration and low oncotic pressure transport of substances, including hormones and 
electrolytes, in the plasma is reduced (Radostits et al., 2007).  The globulin fraction is composed 
of enzymes, carrier proteins, and immunoglobulins.  The concentrations in blood are indicative of 
immune system activity and higher concentrations may indicate an immune response (Keraan et 
al., 1974).   
There has been considerable interest in the potential for spray-dried PP as an opportunity 
to improve the health of calves.  In the swine industry PP are widely used in the diets of weanling 
piglets to improve feed intake and decrease post-weaning diarrhea (van Dijk et al., 2001).  Quigley 
et al. (2002) investigated the use of PP in MR for young calves. They found that calves fed MR 
with PP tended (P < 0.10) to have lower fecal scores and lower use of antibiotics then the all-milk 
control.  Quigley and Wolfe (2003) also reported that calves fed MR containing PP had fewer days 
with scours (fecal score >2) than calves fed the all-milk control.  They did not, however, observe 
a reduction in the use of medications compared to the control.  Similar results were observed in 
the current study.  During the first 3 wk of the study, calves fed the all-milk control had a greater 
probability to have scours and to have scours for a longer duration than calves fed diets containing 
the higher inclusion of PP.  Calves fed the all-milk control or the higher level of PP without amino 
acid supplementation had a higher probability of being medicated and to be medicated for a longer 
duration than calves fed the other MR containing PP.  These results indicate that bovine PP may 
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have beneficial effects on gut health during early life in calves but the amino acid profile must be 
balanced for this beneficial effect to be maximized. 
The immunoglobulin and albumin fractions in PP have been shown to maintain similar 
performance in piglets (Owen et al., 1995).  The immunoglobulins provided in PP have a protective 
effect against the adhesion of some pathogens and so prevent colonization of the enterocytes in 
the intestine (Bosi et al., 2001); this possible local protection by the immunoglobulin fraction may 
explain the improved performance and shorter duration of health incidences for those calves fed 
PP compared to the control.   
The cost of the MR containing bovine PP was less than the control MR with all milk protein 
sources.  During the first 5 wk when only MR was fed the cost per kg of ADG was less for 
treatments 5P, 5PA, and 10PA; however, this was not the case for calves fed treatment 10P.  
Inclusion of PP and amino acids reduced the unit cost of the MR, but at the higher inclusion of PP 
without amino acid supplementation the calves became less efficient so the cost per kilogram of 
ADG was greater than the all-milk control.   
 
CONCLUSIONS 
 In previous research, inclusions of PP higher than 33% CP did not support comparable 
growth to an all-milk control or MR with lower inclusion of PP. In that research, Thr may have 
become limiting at higher inclusion rates.  Results of the current study indicate that with proper 
supplementation of Ile and Thr, growth of calves fed a MR containing 36% CP replaced as PP was 
not different from that of calves fed MR with a lower plasma inclusion rate or an all-milk protein 
MR.  Results indicate that spray-dried bovine PP in MR decreased the occurrence and duration of 
scours in young calves compared to the all-milk control.  Health benefits were greater when Ile 
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and Thr were supplemented to the higher PP inclusion rate.  Overall, results of this study indicate 
that PP is not different in performance and inclusion improved health as long as formulations were 
balanced for Ile and Thr in addition to Met and Lys.    
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TABLES AND FIGURES  
Table 2.1. Ingredient and formulated chemical composition of experimental milk replacers fed to 
dairy calves 
 Treatments1 
Component M 5P 5PA 10P 10PA 
Ingredients      
  Whey, 10.5% CP 23.98 23.61 23.57 24.38 24.91 
  Delactosed whey, 24% CP 20.00 20.00 20.00 20.00 20.00 
  WPC2, 34% CP 10.00 10.00 10.00 8.22 7.26 
  WPC2, 76.2% CP 10.10 4.72 4.54 - - 
  7/60 MR (fat) 10.00 10.00 10.00 10.00 10.00 
  12/50 MR (fat) 23.69 24.30 24.32 24.90 24.94 
  Dicalcium phosphate  0.33 0.17 0.18 - 0.0039 
  Vitamin E, 100,000 PRE 0.13 0.13 0.13 0.13 0.13 
  Mineral Premix3 1.56 1.56 1.56 1.56 1.56 
  DL-Methionine 0.21 0.26 0.26 0.31 0.31 
  98% Tryptophan 0.0124 0.0049 0.0071 - 0.0056 
  Limestone - 0.16 0.16 0.34 0.34 
  Nutra Pro B Plasma4 - 5.00 5.00 10.00 10.00 
  L-Lysine (HCL) 95% PR - 0.09 0.11 0.18 0.21 
  L-Threonine - - 0.05 - 0.10 
  L-Isoleucine - - 0.12 - 0.23 
Nutrient      
  CP, % 22.00 22.00 22.00 22.00 22.00 
  Crude fat, % 20.00 20.00 20.00 20.00 20.00 
  Crude fiber, % - 0.02 0.02 0.03 0.03 
  GE, kcal/kg 4746 4733 4732 4716 4712 
  Lactose, % 40.87 40.55 40.52 40.13 40.02 
  Ca, % 1.12 1.12 1.12 1.12 1.12 
  P, % 0.82 0.82 0.82 0.82 0.82 
  Vitamin A, KIU/lb 30.08 30.05 30.05 30.02 30.02 
  Vitamin D, KIU/lb 10.49 10.49 10.49 10.49 10.49 
  Vitamin E, IU/lb 150.02 150.02 150.02 150.02 150.02 
  Lysine, % 2.04 2.04 2.04 2.04 2.04 
  Methionine, % 0.63 0.63 0.63 0.63 0.63 
  Isoleucine, % 1.33 1.23 1.33 1.12 1.33 
  Threonine, % 1.55 1.51 1.55 1.46 1.55 
  Histidine, % 0.38 0.46 0.46 0.54 0.53 
  Leucine, % 2.30 2.27 2.25 2.23 2.21 
  Valine, % 1.27 1.30 1.29 1.33 1.31 
  Phenylalanine, % 0.73 0.83 0.83 0.93 0.92 
  Tryptophan, % 0.35 0.35 0.35 0.35 0.35 
  Arginine, % 0.57 0.70 0.69 0.83 0.82 
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Table 2.1 (Cont.) 
  Cystine, % 0.50 0.50 0.50 0.50 0.50 
  Tyrosine, % 0.61 0.67 0.66 0.73 0.73 
1 M = all-milk control; 5P = 5% PP; 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 
10PA = 10% PP with Ile and Thr to equal M. 
2 Whey protein concentrate 
3 Milk Specialties Global, Paris, IL.  Proprietary mineral mixture.   
4 APC Inc., Ankeny, IA.
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Table 2.2. Analyzed chemical composition of experimental milk replacers fed to dairy calves (mean ± SD)   
 Treatments1  
Component M 5P 5PA 10P 10PA Starter 
Composite samples, n 3 3 3 3 3 3 
DM, % 96.27±0.35 96.23±0.21 96.30±0.00 96.23±0.25 96.10±0.20 89.40±0.28 
CP, % of DM 22.67±0.12 22.73±0.31 22.90±0.17 22.90±0.26 22.80±0.44 23.75±0.35 
Soluble protein, % of CP 94.67±0.58 95.00±1.00 96.67±0.58 96.33±0.58 97.33±0.58 19.00±1.41 
Crude fat, % of DM 19.9±1.17 19.4±1.31 18.2±1.59 19.2±2.10 18.7±2.01 3.60±0.57 
Ash, % of DM 9.65±0.12 9.92±0.12 10.33±0.07 10.07±0.15 10.12±0.06 7.64±1.43 
Ca, % of DM 1.06±0.10 1.08±0.08 1.09±0.13 1.05±0.12 1.05±0.10 0.89±0.30 
P, % of DM 0.81±0.03 0.87±0.05 0.84±0.06 0.77±0.05 0.76±0.03 0.58±0.11 
Mg, % of DM 0.15±0.01 0.14±0.01 0.14±0.01 0.14±0.01 0.14±0.01 0.28±0.04 
K, % of DM 1.97±0.13 2.0±0.15 2.10±0.19 2.03±0.16 2.04±0.13 1.54±0.11 
Na, % of DM 0.83±0.05 0.92±0.07 0.94±0.08 0.95±0.08 0.94±0.05 0.42±0.19 
S, % of DM 0.38±0.02 0.40±0.03 0.41±0.02 0.41±0.02 0.40±0.01 0.33±0.02 
Fe, ppm 108±21 89±23 93±15 91±16 92±9 189±34 
Zn, ppm 88±15 100±24 90±10 82±3 87±22 111±28 
Cu, ppm 4±2 12±2 6±5 13±14 16±11 26±6 
Mn, ppm 29±5 47±8 47±16 43±4 52±23 96±24 
Mo, ppm 1±0 1±0 1±0 1±0 1±0 2±0 
1 M = all-milk control; 5P = 5% PP; 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with Ile and Thr to 
equal M. 
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Table 2.3. Analyzed amino acid composition (“as is”) of experimental milk replacers fed to dairy calves (mean ± SD) 
 Treatments1  
Item M 5P 5PA 10P 10PA P- Value 
Composite 
samples, n 3 3 3 3 3 
 
Lysine 1.90±0.03 1.95±0.07 1.88±0.03 1.95±0.01 1.93±0.10 0.52 
Methionine 0.57±0.11 0.46±0.03 0.53±0.12 0.45±0.10 0.50±0.16 0.69 
Isoleucine 1.32±0.02a 1.20±0.01b 1.32±0.04a 1.06±0.02c 1.17±0.07b <0.0001 
Threonine 1.49±0.02 1.47±0.03 1.50±0.04 1.44±0.03 1.46±0.03 0.16 
Histidine 0.42±0.04 0.46±0.04 0.46±0.03 0.50±0.04 0.50±0.04 0.15 
Leucine 2.27±0.03a 2.22±0.03ab 2.23±0.02ab 2.16±0.04bc 2.13±0.02c 0.0006 
Valine 1.24±0.04 1.28±0.03 1.27±0.04 1.31±0.02 1.27±0.03 0.20 
Phenylalanine 0.71±0.02c 0.78±0.00b 0.78±0.01b 0.85±0.01a 0.84±0.01a <0.0001 
Tryptophan 0.44±0.01 0.42±0.01 0.43±0.03 0.42±0.02 0.42±0.03 0.48 
Arginine 0.55±0.02c 0.66±0.01b 0.65±0.01b 0.78±0.02a 0.77±0.01a <0.0001 
Cysteine 0.46±0.02 0.50±0.01 0.50±0.02 0.51±0.06 0.51±0.06 0.61 
Tyrosine 0.58±0.05c 0.64±0.02b 0.64±0.02b 0.71±0.01a 0.71±0.02a <0.0001 
Methionine + 
Cysteine 1.03±0.13 0.96±0.03 1.03±0.14 0.97±0.15 1.01±0.21 0.94 
Phenylalanine 
+ Tyrosine 1.28±0.04c 1.42±0.02b 1.42±0.02b 1.57±0.02a 1.55±0.03a <0.0001 
Taurine 0.16±0.05 0.15±0.03 0.15±0.04 0.12±0.03 0.10±0.03 0.31 
Hydroxyproline 0.04±0.03 0.08±0.06 0.09±0.06 0.10±0.07 0.09±0.07 0.81 
Aspartic Acid 2.30±0.03a 2.27±0.03ab 2.27±0.02ab 2.22±0.04bc 2.19±0.02c 0.004 
Serine 1.02±0.04b 1.06±0.03ab 1.06±0.03ab 1.10±0.02a 1.09±0.01ab 0.05 
Glutamic Acid 3.60±0.14a 3.43±0.11ab 3.44±0.10ab 3.26±0.10b 3.23±0.06b 0.008 
Proline 1.26±0.04a 1.22±0.03ab 1.22±0.04 ab 1.17±0.02 ab 1.16±0.03b 0.03 
Glycine 0.46±0.02c 0.51±0.02 b 0.51±0.02 b 0.57±0.01 a 0.56±0.02 a <0.0001 
Alanine 1.07±0.02 1.06±0.02 1.06±0.02 1.05±0.02 1.03±0.01 0.08 
Hydroxylysine 0.04±0.01 0.04±0.01 0.04±0.01 0.04±0.01 0.04±0.01 0.87 
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Table 2.3 (Cont.) 
Ornithine 0.00±0.00 0.00±0.00 0.00±0.01 0.00±0.00 0.00±0.00 0.45 
Total 22.12±0.33 21.97±0.32 22.33±0.63 21.86±0.45 21.78±0.28 0.54 
a,b,c Means within a row with different superscripts differ (P < 0.05). 
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
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Table 2.4. Analyzed amino acid profiles (% of lysine) of experimental milk replacers fed to dairy 
calves 
 Treatments1  
Item M 5P 5PA 10P 10PA P- Value 
Composite 
samples, n 3 3 3 3 3 
 
Lysine 100.0 100.0 100.0 100.0 100.0 - 
Methionine 30.1 23.7 28.3 23.3 26.1 0.59 
Isoleucine 69.4a 61.3b 69.9a 54.5b 60.6b 0.0004 
Threonine 78.4 75.1 79.7 73.8 75.6 0.07 
Histidine 22.1 23.7 24.4 25.9 25.8 0.11 
Leucine 119.9 113.8 118.4 111.0 110.7 0.04 
Valine 65.2 65.7 67.3 67.1 66.1 0.37 
Phenylalanine 37.3c 39.9bc 41.6ab 43.8a 43.8a <0.0001 
Tryptophan 23.4 21.7 22.7 21.5 21.6 0.03 
Arginine 29.2c 33.8b 34.7b 40.1a 40.1a <0.0001 
Cysteine 24.4 25.6 26.6 26.4 26.5 0.81 
Tyrosine 30.4c 32.9b 34.0b 36.6a 36.7a <0.0001 
Methionine + 
Cysteine 63.3 49.3 54.9 49.7 52.6 0.85 
Phenylalanine 
+ Tyrosine 67.7c 72.9b 75.6b 80.5a 80.5a <0.0001 
a,b,c Means within a row with different superscripts differ (P < 0.05).  
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 
10P = 10% PP; 10PA = 10% PP with Ile and Thr to equal M. 
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Table 2.5.  Intakes of dry matter (DM), crude protein (CP), metabolizable energy (ME), and lysine by dairy calves fed experimental 
milk replacers and starter 
a,b Means within a row with different superscripts differ (P < 0.05). 
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
 Treatments1  P-values 
Variable M 5P 5PA 10P 10PA SE Trt Time Trt*Time 
Milk Replacer          
  Wk 1 to 5          
    DM, g/d 767 771 777 753 767 9.1 0.38 <0.0001 0.64 
    CP, g/d 174 175 178 172 175 2.1 0.38 <0.0001 0.69 
    ME, kcal/d 2468 3458 3431 3371 3412 41 0.36 <0.0001 0.63 
    Lysine, g/d 14.73b 15.49a 14.83b 14.61b 15.50a 0.18 <0.0001 <0.0001 0.26 
  Wk 6 to 8          
    DM, g/d 897 912 906 863 913 15.8 0.08 <0.0001 0.70 
    CP, g/d 203 207 207 198 208 3.6 0.12 <0.0001 0.76 
    ME, kcal/d 4054 4093 4000 3863 4058 71 0.09 <0.0001 0.69 
    Lysine, g/d 17.22b 18.34a 17.29b 16.74b 18.44a 0.31 <0.0001 <0.0001 0.41 
Starter, wk 6 to 8          
  DM, g/d 719 826 704 805 797 52.9 0.38 <0.0001 0.93 
  CP, g/d 171 196 167 192 190 12.6 0.38 <0.0001 0.93 
  ME, kcal/d 2226 2684 2290 2615 2590 181 0.26 <0.0001 0.78 
Total, wk 6 to 8          
  DM, g/d 1614 1738 1610 1667 1711 60 0.46 <0.0001 0.81 
  CP, g/d 374 404 375 389 398 14.11 046 <0.0001 0.83 
  ME, kcal/d 6272 6777 6290 6476 6654 210 0.35 <0.0001 0.54 
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Figure 2.1. Milk replacer intake (g/d) by dairy calves fed experimental milk replacers containing plasma protein. 
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Table 2.6.  Body weight and growth measurements of dairy calves fed experimental milk replacers during wk 1 to 5  
a,b Means within a row with different superscripts differ (P < 0.05). 
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
 Treatments1  P-values 
Variable M 5P 5PA 10P 10PA SE Trt Time Trt*Time 
Initial BW, kg 41.7 42.0 41.9 41.7 42.1 1.0 0.97 - - 
Final (wk 5) BW, kg 58.6 59.6 58.8 56.0 59.3 1.7 0.17 - - 
Mean BW, kg  50.7 51.1 51.0 49.5 50.8 0.69 0.45 <0.0001 0.42 
ADG, g/d 479 503 484 411 497 32.38 0.12 <0.0001 0.99 
Gain:feed, kg/kg 0.61ab 0.65a 0.62ab 0.54b 0.65a 0.04 0.03 0.10 0.43 
          
Withers height, cm 81.7 81.4 81.4 81.3 81.4 0.4 0.95 <0.0001 0.45 
  ADG, cm/d 0.17 0.15 0.16 0.15 0.17 0.01 0.61 0.0001 0.30 
Hip height, cm 85.0 85.8 85.0 85.3 85.6 0.4 0.62 <0.0001 0.33 
  ADG, cm/d 0.16 0.20 0.16 0.16 0.19 0.02 0.13 0.006 0.39 
Heart girth, cm 84.9 85.5 85.2 84.8 85.0 0.39 0.72 <0.0001 0.03 
  ADG, cm/d 0.28 0.28 0.26 0.24 0.27 0.02 0.49 <0.0001 0.02 
Body length, cm 79.3 79.0 79.6 79.3 79.5 0.57 0.87 <0.0001 0.74 
  ADG, cm/d 0.27 0.26 0.29 0.27 0.26 0.02 0.74 0.16 0.61 
Hip width, cm 22.3 22.5 22.2 22.3 22.3 0.13 0.28 <0.0001 0.76 
  ADG, cm/d 0.04 0.05 0.04 0.04 0.04 0.01 0.59 0.36 0.50 
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Table 2.7.  Body weight and growth measurements of dairy calves fed experimental milk replacers during wk 1 to 8 
a,b Means within a row with different superscripts differ (P < 0.05). 
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
 Treatments1  P-values 
Variable M 5P 5PA 10P 10PA SE Trt Time Trt*Time 
Initial BW, kg 41.7 42.0 41.9 41.7 42.1 1.0 0.97 - - 
Final BW, kg 82.8 85.3 82.3 79.7 83.9 2.1 0.12 - - 
Mean BW, kg 59.4 60.2 59.6 57.6 59.9 0.86 0.15 <0.0001 0.03 
ADG, g/d 723ab 774a 720ab 670b 752a 27.5 0.05 <0.0001 0.99 
Gain to feed, kg/kg 0.64ab 0.68a 0.65ab 0.58b 0.67ab 0.03 0.01 <0.0001 0.99 
          
Withers height, cm 84.1 83.8 83.8 83.5 83.6 0.39 0.80 <0.0001 0.28 
  ADG, cm/d 0.20 0.19 0.20 0.18 0.18 0.01 0.32 <0.0001 0.18 
Hip height, cm 87.7 88.3 87.5 87.5 87.9 0.43 0.67 <0.0001 0.11 
  ADG, cm/d 0.21 0.21 0.20 0.20 0.21 0.01 0.90 <0.0001 0.60 
Heart girth, cm 89.8 90.1 89.5 89.0 89.6 0.44 0.51 <0.0001 0.006 
  ADG, cm/d 0.38 0.38 0.35 0.36 0.37 0.01 0.16 <0.0001 0.04 
Body length, cm 82.5 82.8 83.3 82.6 83.1 0.56 0.61 <0.0001 0.54 
  ADG, cm/d 0.30 0.33 0.33 0.31 0.34 0.02 0.22 <0.0001 0.80 
Hip width, cm 23.2 23.4 23.0 23.1 23.1 0.15 0.65 <0.0001 0.74 
  ADG, cm/d 0.06 0.06 0.06 0.06 0.06 0.01 0.73 <0.0001 0.31 
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Figure 2.2.  Body weight (kg) of dairy calves fed experimental milk replacers containing plasma protein.  
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Figure 2.3.  Heart girth (cm) of dairy calves fed experimental milk replacers containing plasma protein. 
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Table 2.8.  Concentrations of total protein, urea N, albumin, and globulin in serum samples taken before feeding and 4 h after feeding 
at the end of wk 4 for dairy calves fed experimental milk replacers 
 Treatments1  P-Values 
Variable M 5P 5PA 10P 10PA SE Trt Time Trt*time 
  Total protein, g/dL          
    Overall 5.13 5.15 5.09 5.12 5.18 0.09 0.96 <0.0001 0.11 
    Pre-feeding 5.25 5.26 5.16 5.30 5.35 0.09    
    Post-feeding 5.01 5.03 5.02 4.94 5.01 0.09    
  Urea N, mg/dL          
    Overall 6.95 6.50 6.75 6.55 6.06 0.28 0.20 0.42 0.14 
    Pre-feeding 6.81 6.43 6.80 6.62 6.03 0.28    
    Post-feeding 7.10 6.58 6.70 6.48 6.08 0.28    
  Albumin, g/dL          
    Overall 2.72 2.88 2.72 2.72 2.72 0.04 0.007 <0.0001 0.59 
    Pre-feeding 2.79 2.95 2.77 2.80 2.77 0.04    
    Post-feeding 2.65 2.82 2.67 2.63 2.68 0.04    
  Total globulin, g/dL          
    Overall 2.41 2.26 2.37 2.40 2.46 0.08 0.51 <0.0001 0.07 
    Pre-feeding 2.47 2.31 2.39 2.50 2.58 0.08    
    Post-feeding 2.36 2.22 2.36 2.31 2.34 0.08    
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
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Figure 2.4. Survival analysis of dairy calves fed experimental milk replacers containing plasma protein.  
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Table 2.9.  Initial serum total protein (TP), average fecal score, and electrolyte solution consumption for dairy calves fed experimental 
milk replacers containing plasma protein     
 Treatments1  P-Values 
Variable M 5P 5PA 10P 10PA SE Trt Time Trt*Time 
          
Initial TP, g/dL 5.6 5.7 5.7 5.8 5.8 0.1 0.77 - - 
Average fecal score, d 1 to 21 1.96 1.91 1.96 1.97 1.92 0.04 0.31 <0.0001 0.97 
Total electrolyte consumed, L/calf 0.99 0.27 1.13 1.27 0.27 0.35 0.39 - - 
Electrolyte intake, L/wk per calf 0.02 0.005 0.02 0.02 0.005 0.006 0.01 <0.0001 0.0001 
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
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Table 2.10.  Frequency of electrolyte administration and health events for dairy calves fed milk replacers containing plasma protein1 
 Treatments2  P-Value3 
Variable M 5P 5PA 10P 10PA  Trt 
Calves that received electrolyte        
  Week 1 1/21 0/21 2/20 4/21 1/21  0.18 
  Week 2 4/21 0/21 1/20 2/21 0/20  0.08 
  Week 3 1/21 2/21 2/20 2/21 1/21  0.93 
  Week 4 0/21 1/21 1/20 2/21 1/21  0.72 
  Week 5 0/21 0/21 1/20 0/21 0/21  0.19 
  Week 6 0/21 0/21 0/20 0/21 0/21  - 
  Week 7 0/21 0/21 0/20 0/20 0/21  - 
  Week 8 0/21 0/21 0/20 0/21 0/21  - 
Scours (score > 2)        
  Week 1 2/21 6/21 5/20 5/21 3/21  0.51 
  Week 2 11/21 6/21 6/20 7/21 3/21  0.12 
  Week 3 10/21 10/21 10/19 12/21 9/20  0.94 
  Week 4 8/21 3/21 4/19 11/21 8/20  0.07 
  Week 5 2/21 3/21 0/19 4/21 1/20  0.28 
  Week 6 0/20 1/21 1/19 1/21 0/20  0.73 
  Week 7 0/20 0/21 0/19 2/21 1/20  0.26 
  Week 8 0/20 0/21 0/19 1/20 0/20  0.40 
Respiratory infection (score > 2)        
  Week 1 0/21 0/21 0/20 1/21 0/21  0.41 
  Week 2 0/21 0/21 0/20 0/21 0/21  - 
  Week 3 0/21 0/21 0/19 1/21 0/20  - 
  Week 4 0/21 0/21 0/19 1/21 0/20  - 
  Week 5 0/21 0/21 0/19 1/21 0/20  - 
  Week 6 0/20 0/21 1/19 1/21 0/20  0.08 
  Week 7 0/20 0/21 1/19 0/21 0/20  0.36 
  Week 8 0/20 0/21 1/19 0/20 0/20  0.37 
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Table 2.10 (Cont.) 
1 Values are the number of calves with condition / total number of calves per treatment group. 
2 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 
10% PP with Ile and Thr to equal M. 
3 Chi-square probability for treatment effect. 
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Table 2.11. The logistics model for scours and medication occurrence by comparison of experimental milk replacers containing 
plasma protein fed to dairy calves 
Variable Comparison Coefficient SEM Odds ratio 95% CI P-Value 
Scours occurrence1 (d 1-
21) 
   
   
 M2-10P3 0.3207 0.1566 1.38 1.01-1.88 0.04 
 M-10PA 0.4849 0.1680 1.62 1.17-2.25 0.004 
 5PA-10PA 0.3054 0.1787 1.18 0.95-1.93 0.09 
Medicated1 (All weeks)       
 M-5P 0.9559 0.2624 2.60 1.55-4.35 0.0003 
 M-5PA 1.2264 0.2992 3.41 1.90-6.11 <0.0001 
 M-10PA 0.9046 0.2574 2.47 1.49-4.09 0.0004 
 5P-10P -0.7666 0.2702 0.46 0.27-0.79 0.005 
 5PA-10P -1.0371 0.3062 0.35 0.19-0.64 0.0007 
 10P-10PA 0.7153 0.2654 2.04 1.22-3.46 0.007 
1All other comparisons were not significant P > 0.10. 
2 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
3The OR indicates the probability of either scours or medication for the first treatment in the comparison to the second treatment. If 
the OR is greater than one the first treatment in the comparison is more likely to have either scours or be medicated then the second 
treatment by a factor of the difference above one.  If the OR is less than one the first treatment has a lower probability of occurring 
then the second treatment. 
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Table 2.12.  The Poisson regression for days with scours and days medicated by comparison of treatments of experimental milk 
replacers containing plasma protein fed to dairy calves    
       Contrast2 
Variable Trt1 Coefficient Days SEM 95% CI P-Value 1 2 3 4 
Days with scours (d 1-21) M 1.3122 3.71 0.11 1.09-1.53 - 0.58 0.36 0.06 0.004 
 5P3 1.0588 2.86 0.17 0.49-1.61 0.13     
 5PA3 1.1076 3.03 0.17 0.54-1.66 0.21     
 10P3 0.9898 2.69 0.18 0.42-1.55 0.06     
 10PA3 0.7931 2.21 0.19 0.20-1.37 0.005     
           
Days medicated (All weeks) M 0.8675 2.38 0.14 0.59-1.14 - 0.03 0.30 0.35 0.0003 
 5P3 -0.9676 0.90 0.27 0.22-0.64 0.003     
 5PA3 -1.2242 0.70 0.30 0.16-0.53 <0.0001     
 10P3 -0.1985 1.95 0.21 0.54-1.24 0.35     
 10PA3 -0.9163 0.95 0.26 0.23-0.67 0.0005     
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 10P = 10% PP; 10PA = 10% PP with 
Ile and Thr to equal M. 
1Contrast statements: 1- Amino acid effect (treatment 5P and 10P vs. treatment 5PA and 10PA); 2- Interaction of plasma level and 
AA; (treatment 5P and 5PA vs. treatment 10P and 10PA); 3- Linear plasma level without AA (treatment M, 5P, and 10P); and 4-
Linear plasma level with AA (treatment M, 5PA, and 10PA). 
3All treatments compared to M (control).   
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Table 2.13.  The cost of experimental milk replacers containing plasma protein fed to dairy 
calves 
Treatment Cost of MR2 ($/kg) Cost savings3 ($/kg) Cost/kg ADG4 
M1 3.704 - 6.18 
5P 3.571 -0.13 5.67 
5PA 3.587 -0.12 5.89 
10P 3.448 -0.26 6.91 
10PA 3.479 -0.22 5.51 
1 M = all-milk control; 5P = 5% PP (plasma protein); 5PA = 5% PP with Ile and Thr to equal M; 
10P = 10% PP; 10PA = 10% PP with Ile and Thr to equal M. 
2 Prices quoted by Steve Younker, Milk Specialties Global, as of 17 July 2014 and are for 
comparison only. 
3Difference in cost of treatments compared to M (control).   
4Values shown are for first 5 wk when only milk replacers were fed.   
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CONCLUSIONS 
 Milk replacers are used to feed over 85% of the United States heifer population for at least 
a portion of the preweaning phase (NAHMS, 2011).  With the increasing price of more typical 
protein sources (whey proteins) in the last five years and the estimated human population by 2050, 
milk replacer formulations with alternative proteins need to provide similar growth and health for 
preweaned calves compared to all-milk protein milk replacer formulations.  Results of previous 
research had evaluated the effectiveness of spray-dried plasma proteins as an alternative protein 
source.  However, the successfulness of these formulations is limited to lower inclusion rates 
below 33% of crude protein.  Work in our lab, first by Merriman in 2011 and now with the 
conclusion of this current study to evaluate plasma protein inclusion and amino acid 
supplementation, has shown that up to a 36% inclusion of plasma protein can be successful in 
attaining similar growth to a whey protein milk replacer if certain amino acids are supplemented.  
When it comes down to the bottom line, calves fed higher levels of plasma protein without amino 
acid supplementation did not grow as well, were less efficient, had more health incidences, and 
cost more per kilogram of average daily gain than the other treatments evaluated with plasma 
protein.  Spray-dried plasma protein appear to be a good protein source that can be included in 
milk replacer formulations and will offer a cost effective alternative to the more expensive milk 
based protein formulations.  There also appears to be some non-nutritive benefits that spray-dried 
plasma protein offers, unlike many other alternative protein sources.   
 
 
 
